Key result
Neuromodulation trial retention requires patient-centered strategies and transparent reporting to ensure integrity.
Why the study?
Retention is a critical determinant of trial validity and therapeutic success with implanted medical devices, but concerns persist regarding attrition, incomplete follow-up, and limited generalizability as neuromodulation research expands.
Retention in neuromodulation research and care is a critical issue requiring patient-centered strategies and transparent reporting to improve trial integrity and therapeutic success.
May bias neuromodulation device trial validity; leaves open standardized retention strategies and reporting.
PURPOSE OF REVIEW: Retention is increasingly recognized as a critical determinant of both trial validity and long-term therapeutic success in patients with implanted medical devices. This review is timely because neuromodulation research continues to expand, while concerns remain regarding attrition, incomplete follow-up, and the limited generalizability of available evidence. RECENT FINDINGS: Recent literature indicates that dropout in chronic pain and neuromodulation research is driven by a combination of demographic, psychological, clinical, and structural factors. Pain catastrophizing, low self-efficacy, unrealistic treatment expectations, logistical burden, and dissatisfaction with treatment allocation all contribute to nonretention. Contemporary neuromodulation trials also face additional challenges related to staged treatment pathways, crossover, implantation procedures, and prolonged follow-up, which complicate the definition, reporting, and analysis of attrition. Recent reporting initiatives further highlight persistent inconsistency in participant-flow reporting and missing-data handling in neuromodulation research. SUMMARY: Retention should be viewed not as a secondary logistical issue, but as a shared clinical and research responsibility. Greater emphasis on patient-centered retention strategies, transparent attrition reporting, and rigorous management of missing data is essential to strengthen trial integrity, improve interpretability of neuromodulation evidence, and support durable engagement with implanted device therapy in routine care.
No takes yet. Share an insight, caveat, or question.
Moens et al. (2026) conducted a review in Chronic pain. Implanted medical devices (neuromodulation) was evaluated. Retention in neuromodulation research is driven by demographic, psychological, and structural factors, requiring patient-centered strategies and transparent attrition reporting to improve trial integrity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: